Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte...

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• Myocardial infarction (MI) is a leading cause of mortality globally.
• Chemokine interactions, specifically CCL5 and CXCL4, are implicated in atherosclerosis progression.
• Targeting chemokine pathways presents a potential therapeutic strategy for cardiovascular diseases.

Purpose of the Study:

• To investigate the therapeutic potential of MKEY, a compound designed to block CCL5-CXCR4 interaction, in a mouse model of myocardial ischemia/reperfusion (I/R) injury.
• To evaluate MKEY's efficacy in reducing infarct size, preserving cardiac function, and mitigating inflammation post-I/R.
• To assess MKEY's impact on neutrophil extracellular trap (NET) formation in vivo.

Main Methods:

• Utilized a mouse model of myocardial I/R injury.
• Administered MKEY or a scrambled control (sMKEY) intravenously before and after I/R.
• Assessed cardiac function and infarct size using echocardiography and intraventricular pressure measurements.
• Quantified inflammatory cell infiltration (neutrophils, monocyte/macrophages) and NET formation (citrullinated histone 3 staining).

Main Results:

• MKEY treatment significantly reduced infarct size and preserved cardiac function compared to controls.
• MKEY significantly attenuated the inflammatory response, decreasing neutrophil and monocyte/macrophage infiltration.
• MKEY effectively inhibited neutrophil extracellular trap formation in the infarcted cardiac tissue.

Conclusions:

• Blocking chemokine heterodimers, such as CCL5-CXCR4, with MKEY demonstrates significant cardioprotective effects in I/R injury.
• MKEY reduces myocardial damage and inflammation while potentially maintaining normal immune defense.
• Targeting chemokine interactions offers a promising therapeutic avenue for managing myocardial infarction and related inflammatory conditions.